Novavax Beheer
Beheer criteriumcontroles 2/4
De CEO Novavax is John Jacobs, benoemd in Jan2023, heeft een ambtstermijn van 3.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.86M, bestaande uit 9% salaris en 91% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.19% van de aandelen van het bedrijf, ter waarde $ 2.99M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 5.6 jaar.
Belangrijke informatie
John Jacobs
Algemeen directeur
US$8.9m
Totale compensatie
| Percentage CEO-salaris | 8.95% |
| Dienstverband CEO | 3.5yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 3.5yrs |
| Gemiddelde ambtstermijn bestuur | 5.6yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Jun 17
NVAX: Bearish View Will Hinge On Matrix Licensing Delivering Sustainable Revenue
Analysts have raised their consolidated price target for Novavax stock to $9, an increase of $1 from the previous target of $8. They cite recent research updates that reassess the company's outlook and valuation assumptions.Narratiefupdate • Jun 02
NVAX: Bearish View Will Hinge On Sustained COVID Vaccine Demand Beyond XFG Update
Analysts have lifted their Novavax price target to $9 from $8, citing updated assumptions around slower revenue declines, higher profit margins, and a lower future P/E multiple as key drivers of the change. Analyst Commentary Recent research points to a more cautious tone around Novavax, even as price targets are adjusted.Seeking Alpha • May 30
Novavax: The Pivot To A Royalty Model Is Working, But It's Still A Hold
Summary Novavax maintains a Hold rating as it transitions to a royalty-driven model, with shrinking direct product sales and a focus on partner revenue. NVAX's COVID-19/flu vaccine partnership with Sanofi is operationally ready, but the seasonal COVID-19 market remains niche and unlikely to drive significant upside. Q1 2026 revenue was $140 million, with guidance reaffirmed at $230–$270 million for the year, mostly from royalties; cash runway extends into 2028. Pipeline catalysts, including C. diff vaccine progress and milestone inflows, are largely priced in; meaningful upside requires clinical and financial differentiation. Read the full article on Seeking AlphaNarratiefupdate • Apr 26
NVAX: Bearish View Will Hinge On Sustained COVID Vaccination Demand
Analysts have raised their blended price targets for Novavax by about $1 per share to a range of around $7 to $8, citing updated assumptions for COVID demand, refreshed 2026 revenue and expense forecasts, and the contribution from recent partnership agreements. Analyst Commentary Recent Street research around Novavax reflects a mix of caution and tempered expectations, even as price targets move slightly higher into the mid single digit range.Narratiefupdate • Apr 11
NVAX: Bearish View Will Hinge On Future COVID Demand Execution
Analysts have modestly lifted their average price targets on Novavax shares, with several moving from the $6 to $7 range toward $8 as they update COVID demand assumptions and incorporate new guidance on future revenue, operating expenses, and licensing income. Analyst Commentary Recent Street research on Novavax reflects a cautious tone, even as some targets edge higher.Narratiefupdate • Mar 28
NVAX: Bearish Outlook Will Depend On Pfizer Royalty And COVID Demand Assumptions
Novavax's average analyst price target has edged higher by about $1, as analysts refine their COVID assumptions, update revenue and expense forecasts for future years, and factor recent partnership economics into their models. Analyst Commentary Recent Street research around Novavax points to a cautious tone, even as price targets move slightly higher.Narratiefupdate • Mar 14
NVAX: Cautious Outlook Will Hinge On Future Pfizer Royalty Execution
Narrative Update on Novavax The analyst price target for Novavax has increased by about $1 to a new consensus of $7, as analysts adjust their models for updated COVID demand assumptions, refreshed 2026 revenue and expense forecasts, and the impact of recent partnership and licensing agreements. Analyst Commentary Recent Street research on Novavax points to a mixed but generally cautious stance.
Narratiefupdate • Feb 27
NVAX: Licensing And Royalty Streams Will Drive Future Cash Generation
Analysts have lifted their average price target on Novavax to about $13.78 from roughly $13.11, citing updated COVID demand assumptions, refreshed revenue and expense forecasts, and revised P/E expectations that incorporate recent guidance and licensing agreements. Analyst Commentary Recent Street research reflects a mix of cautious optimism and ongoing concern, with several firms adjusting their price targets and underlying models around Novavax's COVID franchise, expense profile, and licensing income.Analyseartikel • Jan 14
Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 32% in the last...Narratiefupdate • Nov 08
NVAX: Shifting To Licensing Will Drive Royalties And Upfront Payments
Novavax's analyst price target has been modestly reduced from $13.21 to $13.11 per share. This change reflects analysts' cautious optimism about the company's new licensing model, expected royalties, and commercial partnership opportunities.Narratiefupdate • Oct 24
Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead
The analyst price target for Novavax has been raised from $12.50 to $13.21. This reflects analyst confidence in the company’s transition to a licensing model as well as opportunities for revenue from new partnerships and technology platforms.Narratiefupdate • Sep 04
Global Vaccine Market Will Unlock Upside Despite Execution Risks
Novavax’s consensus price target was modestly reduced, primarily due to a slight decline in its future P/E ratio, bringing fair value down from $12.86 to $12.50. What's in the News Reports indicate that the Trump administration and Robert F.Analyseartikel • May 20
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 29% But Investors Aren't Buying For Growth
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 29% in the last...Seeking Alpha • Apr 28
Novavax: Grandiose Ambitions, Smart Strategy, But FDA Decision Adds To Challenges
Summary Novavax's recent performance shows improvement, but significant challenges persist, impacting long-term growth and stability. The company's financials have strengthened due to strategic moves, yet uncertainties in its COVID-19 vaccine remain. NVAX stock's rating maintained at "Hold" despite ongoing hurdles based on improved cash position and potential future opportunities. Investors should remain cautious, balancing optimism with awareness of persistent risks and market volatility. Read the full article on Seeking Alpha
Nieuw narratief • Apr 22
Sanofi Partnership And Pipeline Programs Will Expand Future Markets
Strategic partnerships and new vaccine programs could significantly boost Novavax's future revenue and market expansion efforts.Seeking Alpha • Apr 11
Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer
Summary Novavax's $500M Sanofi partnership with a potential $700M in milestones provides stability as the company transitions to a partnership-focused strategy. Health Secretary Kennedy's claim that single-antigen vaccines don't work for respiratory diseases caused Novavax stock to plummet 20%. FDA approval delay for Nuvaxovid jeopardizes a crucial $175M milestone payment, though Novavax has the financial flexibility to survive this setback. Despite significant regulatory and competitive risks, NVAX stock maintains a "Hold" rating as a speculative component for barbell portfolios. Read the full article on Seeking AlphaAnalyseartikel • Apr 02
The Market Doesn't Like What It Sees From Novavax, Inc.'s (NASDAQ:NVAX) Revenues Yet As Shares Tumble 28%
Novavax, Inc. ( NASDAQ:NVAX ) shareholders that were waiting for something to happen have been dealt a blow with a 28...Analyseartikel • Mar 12
Some Novavax, Inc. (NASDAQ:NVAX) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for Novavax, Inc. ( NASDAQ:NVAX ) shareholders, with the analysts delivering a substantial...Seeking Alpha • Jan 16
Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)
Summary I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of relative weakness. The partnership with Sanofi offers significant benefits but does not assure it of ongoing success. My analysis remains cautious, emphasizing the need for careful consideration of Novavax's long-term viability and strategic moves. Read the full article on Seeking AlphaAnalyseartikel • Dec 17
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 26% in the last...Analyseartikel • Nov 15
Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target
Novavax, Inc. ( NASDAQ:NVAX ) defied analyst predictions to release its third-quarter results, which were ahead of...Seeking Alpha • Nov 13
Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway
Summary Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a substantial cost reduction program set to refocus the company on 4 key value drivers. A collaboration with Sanofi offers flexibility and potential growth, allowing Novavax to focus on developing a COVID-19/influenza combination (CIC) and seasonal influenza vaccines. Despite effective products, reduced guidance and restructuring uncertainty make NVAX stock a hold, with the Sanofi partnership and upcoming milestones as a potential bullish catalyst. Read the full article on Seeking AlphaAnalyseartikel • Nov 01
Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues
Novavax, Inc. ( NASDAQ:NVAX ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Oct 31
Novavax Q3 Earnings A Week Away - Time To Accept A New Reality
Summary Novavax' Q3 earnings are due on 6th November. The vaccine developer was part of Operation Warp Speed, receiving $1.8bn of funding from the US government to develop a COVID vaccine. Novavax succeeded, but Nuvaxovid came to the market too late to build market share and the company ended up making heavy losses. Sanofi has acquired the rights to nuvaxovid, paying Novavax $500m upfront, and will look to develop a COVID / Influenza combo vaccine using Novavax' technology. Unfortunately, Sanofi milestones and revenues aside, that leaves Novavax with few opportunities to generate revenue, which likely means its valuation will fall over time. Read the full article on Seeking AlphaSeeking Alpha • Sep 01
Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones
Summary Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.1 variant, but newer Omicron variants have outpaced it, limiting competitive advantage. Financial stability hinges on achieving key milestones in the Sanofi partnership and successful commercialization of new vaccines. Despite the Sanofi deal, maintaining a "hold" position is prudent given the high-risk nature of Novavax's future prospects. Read the full article on Seeking AlphaAnalyseartikel • Aug 14
Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business
Novavax, Inc.'s ( NASDAQ:NVAX ) price-to-sales (or "P/S") ratio of 2x might make it look like a strong buy right now...Seeking Alpha • Aug 13
Novavax: Staying Long Despite Coming Up Short In Q2
Summary Novavax reported Q2 earnings with a miss on EPS and revenue, causing a drop in share price, but recovered after the earnings call. Novavax is making progress with internal vaccine candidates, Sanofi partnership, and potential market opportunities, despite disappointing Q2 earnings. I provide my thoughts on the quarter, and will highlight a few downside risks that investors should consider. I discuss my updated NVAX strategy. Read the full article on Seeking AlphaAnalyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$88m |
| Dec 31 2025 | US$9m | US$793k | US$440m |
| Sep 30 2025 | n/a | n/a | US$342m |
| Jun 30 2025 | n/a | n/a | US$423m |
| Mar 31 2025 | n/a | n/a | US$479m |
| Dec 31 2024 | US$5m | US$753k | -US$187m |
| Sep 30 2024 | n/a | n/a | -US$285m |
| Jun 30 2024 | n/a | n/a | -US$294m |
| Mar 31 2024 | n/a | n/a | -US$399m |
| Dec 31 2023 | US$7m | US$663k | -US$545m |
Compensatie versus markt: De totale vergoeding ($USD 8.86M ) John } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.14M ).
Compensatie versus inkomsten: De vergoeding van John is gestegen terwijl het bedrijf verliesgevend is.
CEO
John Jacobs (59 yo)
3.5yrs
Tenure
US$8,856,015
Compensatie
Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 3.5yrs | US$8.86m | 0.19% $ 3.0m | |
| Executive VP | 4.9yrs | US$2.99m | 0.079% $ 1.3m | |
| Executive VP | 2.6yrs | US$2.81m | 0.055% $ 877.2k | |
| Executive VP & Chief Strategy Officer | 3.4yrs | US$3.69m | 0.082% $ 1.3m | |
| Executive VP & COO | 3.5yrs | geen gegevens | geen gegevens | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior VP | no data | geen gegevens | geen gegevens | |
| Associate Director of Investor & Public Relations | 8.3yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief Human Resources Officer | 3yrs | geen gegevens | geen gegevens | |
| Executive VP | 4.5yrs | geen gegevens | geen gegevens | |
| Executive VP and Head of Research & Development | 1.7yrs | geen gegevens | 0.021% $ 334.9k |
3.5yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van NVAX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 3.5yrs | US$8.86m | 0.19% $ 3.0m | |
| Chairman of the Board of Directors | 6.1yrs | US$365.59k | 0.049% $ 776.9k | |
| Independent Director | 16.5yrs | US$364.46k | 0.045% $ 713.2k | |
| Independent Vice Chairman of the Board of Directors | 5.6yrs | US$402.28k | 0.027% $ 433.1k | |
| Independent Director | 5.8yrs | US$355.09k | 0.029% $ 464.5k | |
| Independent Director | 7.7yrs | US$353.09k | 0.027% $ 429.2k | |
| Independent Director | 3.8yrs | US$375.45k | 0.029% $ 461.4k | |
| Independent Director | 1.3yrs | US$516.55k | 0.0048% $ 77.4k | |
| Independent Director | 1.5yrs | US$491.95k | 0.0058% $ 92.7k |
5.6yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van NVAX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/06 19:04 |
| Aandelenkoers aan het einde van de dag | 2026/07/02 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Novavax, Inc. wordt gevolgd door 23 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Alec Stranahan | BofA Global Research |
| David Lebowitz | Brean Capital Historical (Janney Montgomery) |
| Mayank Mamtani | B. Riley Securities, Inc. |